Kala Pharmaceuticals (NAS:KALA) Net Income From Continuing Operations

: $-44.82 Mil (TTM As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Kala Pharmaceuticals's net income from continuing operations for the three months ended in Dec. 2022 was $-12.84 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2022 was $-44.82 Mil.

Kala Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Kala Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kala Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Income From Continuing Operations

-66.74

-94.35

-104.33

-142.61

-44.82

Kala Pharmaceuticals Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Net Income From Continuing Operations																-47.57	-32.94	-28.11	29.07	-12.84

Kala Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-44.82 Mil.

Kala Pharmaceuticals (NAS:KALA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kala Pharmaceuticals Inc (NAS:KALA) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

27F0:Germany

Address

1167 Massachusetts Avenue, Arlington, MA, USA, 02476

Website

https://www.kalarx.com

Kala Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. The company's two marketed products are EYSUVIS and INVELTYS.

Executives

Marjan Farid	director	C/O KALA PHARMACEUTICALS, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON MA 02476
Mark S. Blumenkranz	director	C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111
Darius Kharabi	officer: CHIEF BUSINESS OFFICER	C/O KALA PHARMACEUTICALS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
C. Daniel Myers	director	6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Mark T Iwicki	director, officer: Chief Executive Officer	84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Todd Bazemore	officer: Chief Operating Officer	C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Mary Reumuth	officer: Chief Financial Officer	100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
Hongming Chen	officer: Chief Scientific Officer	100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
Romulus K Brazzell	officer: Chief Medical Officer	C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Eric Trachtenberg	officer: See Remarks	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Gregory Grunberg	director	100 BEAVER STREET, WALTHAM MA 02453
Gregory D Perry	director	C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451